CytoDyn to Present at Singular Summer Solstice 2018

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
129
CytoDyn to Present at Singular Summer Solstice 2018 Conference on July 19

VANCOUVER, Washington, July 16, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody, announces that Nader Pourhassan, Ph.D., President and CEO, will present at the Singular Research Summer Solstice 2018 Conference on Thursday, July 19, at 2:50 p.m. Eastern time (11:50 a.m. Pacific time).  The conference is being held at the Convene Conference Center in New York City.

The webcast will be available live and archived at www.singularresearch.com .  Web participants are encouraged to login to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software.

About CytoDyn CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non-HIV, inflammatory indications where CCR5 and its ligand CCL5 may be involved. For more information on the Company, please visit http://www.cytodyn.com .

About PRO 140 PRO 140 is a humanized IgG4 monoclonal antibody that blocks CCR5, a cellular receptor that plays multiple roles with implications in HIV infection, tumor metastasis, and immune signaling.

In the setting of HIV/AIDS, PRO 140 belongs to a new class of therapeutics called viral-entry inhibitors; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. At the same time, PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. PRO 140 has been designated a “fast track” product by the FDA. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 plays a central role in tumor invasion and metastasis, and that an increased CCR5 is an indicator of disease status in several cancers. Moreover, researchers have shown that drugs that block CCR5, including PRO 140, can block tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. CytoDyn is conducting additional research with PRO 140 in the cancer setting and plans to initiate Phase 2 human clinical trials when appropriate. 

The CCR5 receptor also plays a central role in modulating immune cell trafficking to sites of inflammation and it is crucial for the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others have shown that blocking CCR5 using a chemical

inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with PRO 140 to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to PRO 140 for the prevention of graft-versus-host disease (GvHD).

Forward-Looking Statements  This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our current clinical focus, our current and proposed trials and studies and their enrollment, results, costs and completion. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not guarantees of performance and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Form 10-K for the fiscal year ended May 31, 2017 in the section titled “Risk Factors” in Part I, Item 1A and in our Form 10-Q for the quarterly period ended February 28, 2018 in the section titled “Risk Factors” in Part II, Item 1A, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.

Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our Phase 2b/3 pivotal combination therapy trial for PRO 140 (CD02) and to meet the FDA’s requirements with respect to safety and efficacy to support the filing of a Biologics License Application, (iii) our ability to meet our debt obligations, if any, (iv) our ability to identify patients to enroll in our clinical trials in a timely fashion, (v) our ability to achieve approval of a marketable product, (vi) design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (viii) the market for, and marketability of, any product that is approved, (ix) the existence or development of vaccines, drugs, or other treatments for infection with the Human Immunodeficiency Virus that are viewed by medical professionals or patients as superior to our products, (x) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xi) general economic and business conditions, (xii) changes in foreign, political, and social conditions, and (xiii) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.

We intend that all forward-looking statements made in this press release will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable. Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this press release. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

CONTACTS:

Investors: LHA Investor Relations Jody Cain 310-691-7100 jcain@lhai.com

Media: Bioscribe, Inc. Joan E. Kureczka 415-821-2413 Joan@bioscribe.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ajman Forum Puts Algorithmic Messaging Under Scrutiny

Updated Category News Views 11

Algorithms do not merely shuffle posts anymore; they can scramble confidence in the institutions people depend on. That was the serious undercurrent at Ajman Media Forum 2026 – THE SIGNAL, where a session on who leads the government message in an algorithm-driven age brought the discussion back to an uncomfortable reality: communication, cybersecurity and social...

Continue Reading
MetaComp's $10M Extension Tests Stablecoin Rails in Trade

Updated Category News Views 59

A ten-million-dollar check is cheap until the licensing bills start arriving. MetaComp has added roughly US$10 million from Tether and Abu Dhabi-based Further Asset Management, taking its Pre-A and Pre-A+ fundraising to about US$45 million. The important bit is not the headline-sized pile of cash. It is where management says the money is going: licences, compliance...

Continue Reading
LGT Middle East Win Highlights Patient Private Banking

Updated Category News Views 44

A trophy in Dubai is not a balance sheet, but it can be a useful calling card when the clientele measures relationships in decades rather than quarters. LGT Middle East was named Best Pure Play Private Bank at the WealthBriefing MENA Awards 2026, at a ceremony held in Dubai on November 18. For a family-owned wealth manager working with Middle Eastern families, that sort...

Continue Reading
APEC in Shenzhen Puts Trade Openness Back in Focus

Updated Category News Views 68

Shenzhen is hosting a familiar but consequential argument: prosperity gets harder to share when trade channels clog up. At the 33rd Asia-Pacific Economic Cooperation Economic Leaders' Meeting on November 18, President Xi Jinping used the opening of the APEC CEO Summit to argue for peace, openness, innovation, mutual benefit and support for the WTO-centered multilateral...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 210

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 18

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 128

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 159

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading
Endeavor Metals Makes Its Case for Clearer Bullion

Updated Category News Views 27

Gold buyers do not need another velvet-rope sales pitch; they need the math before the handshake. Endeavor Metals Group, a West Palm Beach dealer established in 2013, is pitching something more useful than grand prophecy: a staffed, consultative route into physical gold, silver, platinum, palladium, bullion and collectible coins. In a business where shiny inventory can...

Continue Reading
Jumia’s Breakeven Retreat Invites Legal Scrutiny

Updated Category News Views 154

Jumia’s credibility problem did not arrive wearing a disguise. The company spent much of 2026 telling investors that a fourth-quarter Adjusted EBITDA breakeven was still on the table, then discarded that target after reporting third-quarter results. For holders of NYSE:JMIA, that kind of reversal stings because the promise was not some stray talking point; it was...

Continue Reading

Top 5 Most Recently Viewed Articles

Amazon.com: A Detailed Look at Its Sway in Retail Markets

Updated Category News Views 265

Understanding Amazon.com and Its Competitive Landscape In an ever-changing and highly competitive retail space, analyzing key players is vital for investors and industry experts. This article aims to provide an in-depth evaluation of Amazon.com (NASDAQ: AMZN), delving into its performance compared to major competitors in the broadline retail sector. By thoroughly...

Continue Reading
Navigating the AI Landscape: Nvidia and the Future of Technology

Updated Category News Views 210

Nvidia: The Titan Amid the AI Hype Nvidia (NASDAQ: NVDA) has become a central figure in the tech world, particularly in the booming AI sector. However, some critics argue that the excitement surrounding AI is overshadowing the realistic capabilities of the technology. The true concern lies not with Nvidia, which is currently dealing with constraints in compute resources,...

Continue Reading
Market Insights on Automatic Data Processing's Short Interest

Updated Category News Views 150

Understanding Short Interest in Automatic Data Processing Automatic Data Processing's (ADP) short percent of float has recently dipped by 3.97% compared to its previous report. Currently, the company has reported approximately 4.93 million shares sold short, representing 1.21% of its available trading shares. Based on the current trading activity, it would take traders...

Continue Reading
Thesis Gold Inc. Unveils Compelling Drilling Results for Bingo

Updated Category News Views 159

Thesis Gold Inc. Reports Exciting Drilling Results at Bingo Zone Thesis Gold Inc. (TSXV: TAU) has recently revealed outstanding drilling outcomes from its Bingo Zone, marking a pivotal moment in the company’s ongoing exploration at its wholly-owned Lawyers-Ranch Project. This project is nestled within a highly regarded mining region, and the recent discoveries promise...

Continue Reading
October Distributions Announced by Roundhill Investments ETFs

Updated Category News Views 52

Roundhill Investments Announces ETF Distributions Roundhill Investments, a leading ETF sponsor known for its innovative financial products, recently announced the distributions for several of its exchange-traded funds (ETFs) including XDTE, QDTE, and RDTE, effective this October. This news is particularly relevant for investors looking to stay informed about their...

Continue Reading